Gyre Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Gyre Therapeutics, Inc. (GYRE) had Operating Lease, Weighted Average Discount Rate, Percent of 7.41% as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-07
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 7.41%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 4.75%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.81%; Operating Lease, Weighted Average Discount Rate, Percent as first filed 4.76%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 4.76%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 7.41% 10-Q · filed 2026-08-07 | |
| 2026-03-31 | 4.75% 10-Q · filed 2026-05-08 | |
| 2025-12-31 | 7.81% 10-Q · filed 2026-08-07 | 4.76% 10-K · filed 2026-03-13 |
| 2025-09-30 | 4.76% 10-Q · filed 2025-11-07 | |
| 2025-06-30 | 4.76% 10-Q · filed 2025-08-11 | |
| 2025-03-31 | 4.76% 10-Q · filed 2025-05-09 | |
| 2024-12-31 | 4.76% 10-K · filed 2026-03-13 | |
| 2024-09-30 | 4.76% 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 4.76% 10-Q · filed 2024-08-13 | |
| 2024-03-31 | 4.80% 10-Q · filed 2024-05-13 | |
| 2023-12-31 | 4.78% 10-K · filed 2025-03-17 | |
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 4.75% 10-K · filed 2024-03-27 | 4.30% 10-K · filed 2023-03-30 |
| 2022-09-30 | 5.70% 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 4.80% 10-Q · filed 2022-08-15 | |
| 2022-03-31 | 4.80% 10-Q · filed 2022-05-09 | |
| 2021-12-31 | 4.80% 10-K · filed 2023-03-30 | |
| 2021-09-30 | 4.90% 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 4.90% 10-Q · filed 2021-08-05 | |
| 2021-03-31 | 5.70% 10-Q · filed 2021-05-06 | |
| 2020-12-31 | 5.70% 10-K · filed 2022-03-31 | |
| 2020-09-30 | 6.00% 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 6.00% 10-Q · filed 2020-08-06 | |
| 2020-03-31 | 6.00% 10-Q · filed 2020-05-11 | |
| 2019-12-31 | 6.00% 10-K · filed 2021-03-04 | |
| 2019-09-30 | 6.00% 10-Q · filed 2019-11-07 | |
| 2019-06-30 | 6.00% 10-Q · filed 2019-08-01 | |
| 2019-03-31 | 6.00% 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |